EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, RaQualia Pharma's Enterprise Value is 円10,471 Mil.
RaQualia Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was 円264 Mil. Therefore, RaQualia Pharma's EV-to-FCF for today is 39.67.
The historical rank and industry rank for RaQualia Pharma's EV-to-FCF or its related term are showing as below:
TSE:4579'
s EV-to-FCF Range Over the Past 10 Years
Min: -818.95 Med: -32.67 Max: 668.06
Current: 40.95
During the past 13 years, the highest EV-to-FCF of RaQualia Pharma was 668.06. The lowest was -818.95. And the median was -32.67.
TSE:4579's EV-to-FCF is ranked worse than 72.48% of 327
companies
in the Biotechnology industry
Industry Median: 16.69
vs TSE:4579: 40.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
RaQualia Pharma's PE Ratio (TTM) for today is calculated as:
RaQualia Pharma's share price for today is 円468.00.
RaQualia Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-24.090.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
RaQualia Pharma EV-to-FCF Related Terms
RaQualia Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for RaQualia Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4579 vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, RaQualia Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RaQualia Pharma EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RaQualia Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where RaQualia Pharma's EV-to-FCF falls into.
RaQualia Pharma's current Enterprise Value is 円10,471 Mil.
RaQualia Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円264 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RaQualia Pharma (TSE:4579) has a EV-to-FCF of 39.67 as of Jul. 08, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on RaQualia Pharma and its competitors. According to the industry distribution chart, RaQualia Pharma ranks #237 out of 327 companies in the Biotechnology industry, placing it in the top 72.5%.
Is RaQualia Pharma's EV-to-FCF too high?
RaQualia Pharma's current EV-to-FCF is 39.67. The Biotechnology industry median EV-to-FCF is 16.69. RaQualia Pharma's value of 39.67 is 137.7% above this industry median. Based on the distribution chart, RaQualia Pharma ranks #237 out of 327 companies in the Biotechnology industry, which is below the industry midpoint. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #237 out of 327 companies for EV-to-FCF. This places RaQualia Pharma in the lower half of its industry. The industry median EV-to-FCF is 16.69. RaQualia Pharma's value of 39.67 is 137.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.69, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RaQualia Pharma's current EV-to-FCF of 39.67 is 137.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on RaQualia Pharma and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RaQualia Pharma's current EV-to-FCF is 39.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円961.31, compared to a current price of 円468.00 — trading 51.3% below its estimated fair value. The current EV-to-FCF is 39.67 and 137.7% above the Biotechnology industry median of 16.69. RaQualia Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current EV-to-FCF is 39.67 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RaQualia Pharma (TSE:4579) Overvalued in 2026?
Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued.
The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.31.
GuruFocus considers RaQualia Pharma to be Significantly Undervalued.
Key valuation signals for TSE:4579:
EV-to-FCF: 39.67
GF Value™: 円961.31 vs. price of 円468.00 (51.3% below fair value)
Industry Position: 137.7% above the Biotechnology median (#237 of 327)
No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
57GF Score
Get the complete analysis for TSE:4579
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4579 has been successfully added to your 
